2/6
07:30 am
ntla
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2/5
02:00 pm
ntla
Intellia Therapeutics: 2 Major Catalysts Will Determine Stock's Trajectory In 2026 [Seeking Alpha]
Low
Report
Intellia Therapeutics: 2 Major Catalysts Will Determine Stock's Trajectory In 2026 [Seeking Alpha]
2/2
09:40 am
ntla
Baird Updates Intellia Therapeutics, Inc. (NTLA)'s Financial Model Following Nex-Z Clinical Hold Removal [Yahoo! Finance]
Low
Report
Baird Updates Intellia Therapeutics, Inc. (NTLA)'s Financial Model Following Nex-Z Clinical Hold Removal [Yahoo! Finance]
1/28
05:49 pm
ntla
NTLA Stock Up More Than 6% as FDA Lifts ATTRv-PN Study Clinical Hold [Yahoo! Finance]
Low
Report
NTLA Stock Up More Than 6% as FDA Lifts ATTRv-PN Study Clinical Hold [Yahoo! Finance]
1/28
10:59 am
ntla
Intellia Therapeutics (NASDAQ:NTLA) was given a new $25.00 price target on by analysts at KeyCorp.
Low
Report
Intellia Therapeutics (NASDAQ:NTLA) was given a new $25.00 price target on by analysts at KeyCorp.
1/28
09:52 am
ntla
Intellia Therapeutics (NTLA) Surges 6.3%: Is This an Indication of Further Gains? [Yahoo! Finance]
Low
Report
Intellia Therapeutics (NTLA) Surges 6.3%: Is This an Indication of Further Gains? [Yahoo! Finance]
1/28
08:05 am
ntla
Cutting DNA, Cutting Edge: Companies Using CRISPR and Other Gene Editing Technologies to Rewrite the Future of Industry and Medicine
Medium
Report
Cutting DNA, Cutting Edge: Companies Using CRISPR and Other Gene Editing Technologies to Rewrite the Future of Industry and Medicine
1/28
07:19 am
ntla
Intellia Therapeutics (NASDAQ:NTLA) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Medium
Report
Intellia Therapeutics (NASDAQ:NTLA) had its "buy" rating reaffirmed by analysts at HC Wainwright.
1/27
03:02 pm
ntla
Intellia Therapeutics (NASDAQ:NTLA) was given a new $7.00 price target on by analysts at Robert W. Baird.
Medium
Report
Intellia Therapeutics (NASDAQ:NTLA) was given a new $7.00 price target on by analysts at Robert W. Baird.
1/27
12:28 pm
ntla
FDA lifts hold on an Intellia CRISPR drug trial [Yahoo! Finance]
Low
Report
FDA lifts hold on an Intellia CRISPR drug trial [Yahoo! Finance]
1/27
08:33 am
ntla
US FDA lifts clinical hold on Intellia's nerve disease trial [Yahoo! Finance]
High
Report
US FDA lifts clinical hold on Intellia's nerve disease trial [Yahoo! Finance]
1/27
08:32 am
ntla
Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE-2 Phase 3 Clinical Trial in ATTRv-PN [Yahoo! Finance]
High
Report
Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE-2 Phase 3 Clinical Trial in ATTRv-PN [Yahoo! Finance]
1/27
08:00 am
ntla
Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE-2 Phase 3 Clinical Trial in ATTRv-PN
Low
Report
Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE-2 Phase 3 Clinical Trial in ATTRv-PN
1/24
05:08 am
ntla
Intellia Therapeutics (NASDAQ:NTLA) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Intellia Therapeutics (NASDAQ:NTLA) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
1/21
01:16 am
ntla
Intellia Therapeutics: Maintaining A Sell Rating As Platform Risks Escalate [Seeking Alpha]
Medium
Report
Intellia Therapeutics: Maintaining A Sell Rating As Platform Risks Escalate [Seeking Alpha]
1/20
12:26 am
ntla
Is Intellia Therapeutics (NTLA) Pricing Make Sense After Recent 35% Monthly Surge [Yahoo! Finance]
Low
Report
Is Intellia Therapeutics (NTLA) Pricing Make Sense After Recent 35% Monthly Surge [Yahoo! Finance]
1/18
01:00 am
ntla
Intellia Therapeutics (NASDAQ:NTLA) was downgraded by analysts at
Wall S
Low
Report
Intellia Therapeutics (NASDAQ:NTLA) was downgraded by analysts at
Wall S
1/12
05:26 am
ntla
Intellia CEO Sells $314K in Stock While Holding Over 1 Million Shares [Yahoo! Finance]
High
Report
Intellia CEO Sells $314K in Stock While Holding Over 1 Million Shares [Yahoo! Finance]
1/10
07:02 pm
ntla
Fred Cohen Buys 303% More Intellia Therapeutics Shares [Yahoo! Finance]
High
Report
Fred Cohen Buys 303% More Intellia Therapeutics Shares [Yahoo! Finance]
1/7
07:12 pm
ntla
Intellia Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
Low
Report
Intellia Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
1/7
07:30 am
ntla
Intellia Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Low
Report
Intellia Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
1/5
01:03 pm
ntla
Intellia Stock Declines Around 55% in 3 Months: Here's Why [Yahoo! Finance]
Low
Report
Intellia Stock Declines Around 55% in 3 Months: Here's Why [Yahoo! Finance]
1/3
10:01 am
ntla
We Think Intellia Therapeutics (NASDAQ:NTLA) Needs To Drive Business Growth Carefully [Yahoo! Finance]
Low
Report
We Think Intellia Therapeutics (NASDAQ:NTLA) Needs To Drive Business Growth Carefully [Yahoo! Finance]
1/2
04:01 pm
ntla
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12/31
06:32 am
ntla
Cathie Wood Doubles Down on Biotech as 2025 Ends, Offloads Rocket Lab [Yahoo! Finance]
Low
Report
Cathie Wood Doubles Down on Biotech as 2025 Ends, Offloads Rocket Lab [Yahoo! Finance]